Skip to main content
Log in

Drug-Induced Taste Disorders

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Numerous drugs have the potential to adversely influence a patient’s sense of taste, either by decreasing function or producing perceptual distortions or phantom tastes. In some cases, such adverse effects are long lasting and cannot be quickly reversed by drug cessation. In a number of cases, taste-related adverse effects significantly alter the patient’s quality of life, dietary choices, emotional state and compliance with medication regimens. In this review, we describe common drug-related taste disturbances and review the major classes of medications associated with them, including antihypertensives, antimicrobials and anti-depressants. We point out that there is a dearth of scientific information related to this problem, limiting our understanding of the true nature, incidence and prevalence of drug-related chemosensory disturbances. The limited data available suggest that large differences exist among individuals in terms of their susceptibility to taste-related adverse effects, and that sex, age, body mass and genetic variations in taste sensitivity are likely involved. Aside from altering drug usage, management strategies for patients with taste-related adverse effects are sorely needed. Unfortunately, stopping a medication is not always an easy option, particularly when one is dealing with life-threatening conditions such as seizures, cancer, infection, diabetes mellitus and uncontrolled hypertension. Hopefully, the information contained in this review will sensitize physicians, researchers and drug manufacturers to this problem and will result in much more research on this pressing topic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am 2002; 46(4): 857–68

    Article  PubMed  Google Scholar 

  2. Marks HM. Revisiting the origins of compulsory drug prescriptions. Am J Public Health 1995; 85(1): 109–15

    Article  PubMed  CAS  Google Scholar 

  3. Ciancio SG. Medications’ impact on oral health. J Am Dent Assoc 2004; 135(10): 1440–8

    PubMed  Google Scholar 

  4. Physicians’ Desk Reference. Montvale (NJ): Medical Economics Company, Inc., 2005

  5. Lewis IK, Hanlon JT, Hobbins MJ, et al. Use of medications with potential oral adverse drug reactions in community-dwelling elderly. Spec Care Dentist 1993; 13(4): 171–6

    Article  PubMed  CAS  Google Scholar 

  6. Shinkai RS, Hatch JP, Schmidt CB, et al. Exposure to the oral side effects of medication in a community-based sample. Spec Care Dentist 2006; 26(3): 116–20

    Article  PubMed  Google Scholar 

  7. Ahne G, Erras A, Hummel T, et al. Assessment of gustatory function by means of tasting tablets. Laryngoscope 2000 Aug; 110(8): 1396–401

    Article  PubMed  CAS  Google Scholar 

  8. Doty RL. Office procedures for quantitative assessment of olfactory function. Amer J Rhinol 2007; 21(4): 460–73

    Article  Google Scholar 

  9. Deems DA, Doty RL, Settle RG, et al. Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otolaryngol Head Neck Surg 1991; 117(5): 519–28

    Article  PubMed  CAS  Google Scholar 

  10. Burdach KJ, Doty RL. The effects of mouth movements, swallowing, and spitting on retronasal odor perception. Physiol Behav 1987; 41(4): 353–6

    Article  PubMed  CAS  Google Scholar 

  11. Byrne BE. Oral manifestations of systemic agents. In: Ciancio SG, editor. ADA®/PDR® guide to dental therapeutics. 4th ed. Montvale (NJ): Thomson PDR, 2006: 835–9

    Google Scholar 

  12. Keiser HR, Henkin RI, Bartter FC, et al. Loss of taste during therapy with penicillamine. JAMA 1968; 203(6): 381–3

    Article  PubMed  CAS  Google Scholar 

  13. Fogan L. Griseofulvin and dysgeusia: implications? Ann Intern Med 2007; 74: 795–6

    Google Scholar 

  14. Bromley SM, Doty RL. Clinical disorders affecting taste: evaluation and management. In: Doty RL, editor. Handbook of olfaction and gustation. New York: Marcel Dekker, 2003: 935–57

    Google Scholar 

  15. Ishizaka T, Miyanaga Y, Mukai J, et al. Bitterness evaluation of medicines for pediatric use by a taste sensor. Chem Pharm Bull 2004; 52(8): 943–8

    Article  PubMed  CAS  Google Scholar 

  16. Schiffman SS, Zervakis J, Westall HL, et al. Effect of antimicrobial and anti-inflammatory medications on the sense of taste. Physiol Behav 2000; 69(4–5): 413–24

    Article  PubMed  CAS  Google Scholar 

  17. Juhlin L. Loss of taste and terbinafine [letter]. Lancet 1992; 339(8807): 1483

    Article  PubMed  CAS  Google Scholar 

  18. Beutler M, Hartmann K, Kuhn M, et al. Taste disorders and terbinafine [letter]. BMJ 1993: 307: 26

    Article  PubMed  CAS  Google Scholar 

  19. Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol 1998; 139(4): 747–8

    Article  PubMed  CAS  Google Scholar 

  20. Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope 2005; 115(11): 2035–7

    Article  PubMed  CAS  Google Scholar 

  21. Stricker BH, Van RM, Sturkenboom MC, et al. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol 1996; 42(3): 313–8

    Article  PubMed  CAS  Google Scholar 

  22. Granger EM, Glendinning JI, Smith JC, et al. Behavioral and electrophysiological responses to NaCl in young and old fisch-er-344 rats. Chem Senses 1993; 18(4): 419–26

    Article  CAS  Google Scholar 

  23. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43(2): 259–84

    Article  PubMed  CAS  Google Scholar 

  24. Doty RL, Philip S, Reddy K, et al. Influences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smell: a review. J Hypertens 2003; 21(10): 1805–13

    Article  PubMed  CAS  Google Scholar 

  25. Hellekant G, Danilova V, Ninomiya Y. Primate sense of taste: behavioral and single chorda tympani and glossopharyngeal nerve fiber recordings in the rhesus monkey, Macaca mulatta. J Neurophysiol 1997; 77(2): 978–93

    PubMed  CAS  Google Scholar 

  26. Eiznhamer DA, Creagh T, Ruckle JL, et al. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials 2002; 3(6): 435–50

    Article  PubMed  Google Scholar 

  27. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav 2003; 7(2): 109–17

    Article  PubMed  Google Scholar 

  28. Eksborg S, Pal N, Kalin M, et al. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002; 38(4): 240–6

    Article  PubMed  Google Scholar 

  29. Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992; 36(4): 727–32

    Article  PubMed  CAS  Google Scholar 

  30. Hsyu PH, Pithavala YK, Gersten M, et al. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 2002; 2002 Feb; 46(2): 392–7

    Article  PubMed  CAS  Google Scholar 

  31. Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytome-galovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47(4): 1334–42

    Article  PubMed  CAS  Google Scholar 

  32. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. JAMA 1998; 279(24): 1962–7

    Article  PubMed  CAS  Google Scholar 

  33. Marshall S. Zinc gluconate and the common cold. Review of randomized controlled trials. Can Fam Phy 1998; 44: 1037–42

    CAS  Google Scholar 

  34. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996; 125(2): 81–8

    PubMed  CAS  Google Scholar 

  35. Tanaka M. Secretory function of the salivary gland in patients with taste disorders or xerostomia: correlation with zinc deficiency. Acta Otolaryngol Suppl 2002; (546): 134–41

  36. Bergman U, Ostergren A, Gustafson AL, et al. Differential effects of olfactory toxicants on olfactory regeneration. Arch Toxicol 2002; 76(2): 104–12

    Article  PubMed  CAS  Google Scholar 

  37. Oakley B, Riddle DR. Receptor cell regeneration and connectivity in olfaction and taste. Exp Neurol 1992; 115(1): 50–4

    Article  PubMed  CAS  Google Scholar 

  38. Zain RB, Hanks CT. Morphological changes in taste buds of the fungiform papillae after a single dose of x-ray irradiation in rats. Malays J Pathol 1989; 11: 57–64

    PubMed  CAS  Google Scholar 

  39. Nakamura H, Nonomura N, Fujiwara M, et al. Olfactory disturbances caused by the anti-cancer drug tegafur. Eur Arch Otorhinolaryngol 1995; 252(1): 48–52

    Article  PubMed  CAS  Google Scholar 

  40. Epstein JB, Phillips N, Parry J, et al. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2002; 30(11): 785–92

    Article  PubMed  CAS  Google Scholar 

  41. Wickham RS, Rehwaldt M, Kefer C, et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999; 26(4): 697–706

    PubMed  CAS  Google Scholar 

  42. Bergström U, Giovanetti A, Piras E, et al. Methimazole-induced damage in the olfactory mucosa: effects on ultrastructure and glutathione levels. Tox Path 2003; 31: 379–87

    Article  Google Scholar 

  43. Kiewe P, Jovanovic S, Thiel E, et al. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin. Ann Pharmacother 2004; 38(7–8): 1212–4

    Article  PubMed  Google Scholar 

  44. Hallman BL, Hurst JW. Loss of taste as a toxic effect of methimazole (tapazole) therapy: report of three cases [letter]. J Amer Med Assoc 1953; 152: 322

    Article  CAS  Google Scholar 

  45. McConnell RJ, Menendez CE, Smith FR, et al. Defects of taste and smell in patients with hypothyroidism. Am J Med 1975; 59(3): 354–64

    Article  PubMed  CAS  Google Scholar 

  46. Genter MB, Owens DM, Carlone HB, et al. Characterization of olfactory deficits in the rat following administration of 2,6-dichlorobenzonitrile (dichlobenil), 3,3′-iminodipropionitrile, or methimazole. Fundam Appl Toxicol 1996; 29(1): 71–7

    Article  PubMed  CAS  Google Scholar 

  47. Xu W, Slotnick B. Olfaction and peripheral olfactory connections in methimazole-treated rats. Behav Brain Res 1999; 102(1–2): 41–50

    Article  PubMed  CAS  Google Scholar 

  48. Sitzia J, North C, Stanley J, et al. Side effects of CHOP in the treatment of non-Hodgkins’s lymphoma. Cancer Nurs 1997; 20(6): 430–9

    Article  PubMed  CAS  Google Scholar 

  49. Brosvic GM, Doty RL, Rowe MM, et al. Influences of hypothyroidism on the taste detection performance of rats: a signal detection analysis. Behav Neurosci 1992; 106(6): 992–8

    Article  PubMed  CAS  Google Scholar 

  50. Boyd I. Captopril-induced taste disturbance [letter]. Lancet 1993; 342: 304

    Article  PubMed  CAS  Google Scholar 

  51. Zervakis J, Graham BG, Schiffman SS. Taste effects of lingual application of cardiovascular medications. Physiol Behav 2000 Jan; 68(3): 405–13

    Article  PubMed  CAS  Google Scholar 

  52. Griffin JP. Drug-induced disorders of taste. Adverse Drug React Toxicol Rev 1992; 11(4): 229–39

    PubMed  CAS  Google Scholar 

  53. DiBianco R. ACE inhibitors in the treatment of heart failure. Clin Cardiol 1990; 13 (6 Suppl. 7): VII32–8

    PubMed  CAS  Google Scholar 

  54. Grosskopf I, Rabinovitz M, Garty M, et al. Persistent captopril-associated taste alteration [letter]. Clin Pharm 1984; 3(3): 235

    PubMed  CAS  Google Scholar 

  55. McNeil JJ, Anderson A, Christophidis N, et al. Taste loss associated with oral captopril treatment. BMJ 1979; 2: 1555–6

    Article  PubMed  CAS  Google Scholar 

  56. Unnikrishnan D, Murakonda P, Dharmarajan TS. If it is not cough, it must be dysgeusia: differing adverse effects of angio-tensin-converting enzyme inhibitors in the same individual. J Am Med Dir Assoc 2004; 5(2): 107–10

    Article  PubMed  CAS  Google Scholar 

  57. Heeringa M, van PE. Reversible dysgeusia attributed to losartan [letter]. Ann Intern Med 1998; 129(1): 72

    PubMed  CAS  Google Scholar 

  58. Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan [letter]. Lancet 1996; 347(8999): 471–2

    Article  PubMed  CAS  Google Scholar 

  59. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydroclorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75(12): 793–5

    Article  PubMed  CAS  Google Scholar 

  60. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51(5): 820–45

    Article  PubMed  CAS  Google Scholar 

  61. Levenson JL, Kennedy K. Dysosmia, dysgeusia, and nifedipine. Ann Intern Med 1985; 102(1): 135–6

    PubMed  CAS  Google Scholar 

  62. Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am 2002; 46: 857–68

    Article  PubMed  Google Scholar 

  63. Appel LJ. The verdict from ALLHAT: thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288(23): 3039–42

    Article  PubMed  Google Scholar 

  64. Roitman MF, Bernstein IL. Amiloride-sensitive sodium signals and salt appetite: multiple gustatory pathways. Am J Physiol Regul Integr Comp Physiol 1999; 276(6): 1732–8

    Google Scholar 

  65. Roper SD. Signal transduction and information processing in mammalian taste buds. Pflugers Arch 2007; 454(5): 759–76

    Article  PubMed  CAS  Google Scholar 

  66. Anand KK, Zuniga JR. Effect of amiloride on suprathreshold NaCl, LiCl, and KCl salt taste in humans. Physiol Behav 1997; 62(4): 925–9

    Article  PubMed  CAS  Google Scholar 

  67. Mattes RD, Christensen CM, Engelman K. Effects of therapeutic doses of amiloride and hydrochlorothiazide on taste, saliva, and salt intake in normotensive adults. Chem Senses 1988; 13: 33–44

    Article  CAS  Google Scholar 

  68. McMurdo ME, Hutchinson GL, Lindsay G. Taste disturbance with acetazolamide. Lancet 1990; 336(8724): 1190–1

    Article  PubMed  CAS  Google Scholar 

  69. Leaf A, Schwartz WB, Relman AS. Oral administration of a potent carbonic anhydrase inhibitor (Diamox): I. Changes in electrolyte and acid-base balance. N Engl J Med 1954; 250(18): 759–64

    Article  PubMed  CAS  Google Scholar 

  70. Kennedy WA, Laurier C, Gautrin D, et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epid 2000; 53(97): 696–701

    Article  CAS  Google Scholar 

  71. Mitchell JC, Counselman FL. A taste comparison of three different liquid steroid preparations: prednisone, prednisolone, and dexamethasone. Acad Emerg Med 2003; 10(4): 400–3

    Article  PubMed  Google Scholar 

  72. Bachert C, El Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89(3): 292–7

    Article  PubMed  Google Scholar 

  73. Regan TD, Lewis D, Norton SA. Taste comparison of corticosteroid suspensions. J Drugs Dermatol 2006; 5(9): 835–7

    PubMed  Google Scholar 

  74. Kratskin IL, Kimura Y, Hastings L, et al. Chronic dexamethasone treatment potentiates insult to olfactory receptor cells produced by 3-methylindole. Brain Res 1999; 847(2): 240–6

    Article  PubMed  CAS  Google Scholar 

  75. Schiffman SS, Graham BG, Suggs MS, et al. Effect of psychotropic drugs on taste responses in young and elderly persons. Ann NY Acad Sci 1998; 855: 732–7

    Article  PubMed  CAS  Google Scholar 

  76. Schiffman SS, Zervakis J, Suggs MS, et al. Effect of medications on taste: example of amitriptyline HC1. Physiol Behav 1999; 66(2): 183–91

    Article  PubMed  CAS  Google Scholar 

  77. Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by drugs. Pharmacotherapy 1997; 17: 482–96

    PubMed  CAS  Google Scholar 

  78. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995; 40(11): 983–9

    Article  PubMed  CAS  Google Scholar 

  79. Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3(2): 131–40

    Article  PubMed  CAS  Google Scholar 

  80. Padala KP, Hinners CK, Padala PR. Mirtazapine therapy for dysgeusia in an elderly patient. J Clin Psychiatry 2007; 8: 178–80

    Google Scholar 

  81. Scharf MB, Roth PB, Dominguez RA, et al. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in patients with insomnia. J Clin Pharmacol 1990; 30(5): 461–7

    PubMed  CAS  Google Scholar 

  82. Berridge KC, Peciña S. Benzodiazepines, appetite, and taste palatability. Neurosci Biobehav Rev 1995; 19(1): 121–31

    Article  PubMed  CAS  Google Scholar 

  83. Caldwell EE, Wallace P, Taylor SP. Use of an analog task to study effects of diazepam on taste perception, consummatory behaviors, and risk taking in a social context. J Gen Psychol 2004; 13(2): 101–17

    Article  Google Scholar 

  84. Abdullahi M, Radfar M. A review of drug induced oral reactions. J Cont Dent Prac 2005; 4(1): 1–22

    Google Scholar 

  85. Tyssen A, Remmerie B, Eng C, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther 2007; 29(2): 290–304

    Article  CAS  Google Scholar 

  86. Bressler B. An unusual side-effect of lithium. Psychosomatics 1980; 21(8): 688–9

    PubMed  CAS  Google Scholar 

  87. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort: 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiat Scand 1988; 78(4): 434–41

    Article  PubMed  CAS  Google Scholar 

  88. Duffield JE. Side effects of lithium carbonate [letter]. BMJ 1973; 1(5851): 491

    Article  PubMed  CAS  Google Scholar 

  89. Himmelhoch JM, Hanin I. Letter: Side effects of lithium carbonate. BMJ 1974; 4(5938): 233

    Article  PubMed  CAS  Google Scholar 

  90. Grupta KD, Jefferson JW. Lithium and “accidentally” induced food aversion [letter]. J Clin Psychiatry 1980; 41(10): 364

    PubMed  CAS  Google Scholar 

  91. Mizielinska SM. Ion channels in epilepsy. Biochem Soc Trans 2007; 35 (Pt 5): 1077–9

    Article  PubMed  CAS  Google Scholar 

  92. Onat F, Ozkara C. Adverse effects of new antiepileptic drugs. Drugs Today 2004; 40(4): 325–42

    Article  PubMed  CAS  Google Scholar 

  93. Zeller JA, Machetanz J, Kessler C. Ageusia as an adverse effect of phenytoin treatment. Lancet 1998; 352: 68

    Article  Google Scholar 

  94. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291(8): 965–73

    Article  PubMed  CAS  Google Scholar 

  95. Silberstein S, Loder E, Forder G, et al. The impact of migraine on daily activities: effect of topiramate compared to placebo. Curr Med Res Opin 2006; 22: 1021–9

    Article  PubMed  CAS  Google Scholar 

  96. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41(10): 968–75

    Article  PubMed  CAS  Google Scholar 

  97. Nakazato Y, Imai K, Abe T, et al. Unpleasant sweet taste: a symptom of SIADH caused by lung cancer. J Neurol Neurosurg Psychiat 2006; 77(3): 405–6

    Article  PubMed  CAS  Google Scholar 

  98. Panayiotou H, Small SC, Hunter JH, et al. Sweet taste (dysgeusia). The first symptom of hyponatremia in small cell carcinoma of the lung. Arch Intern Med 1995; 155(12): 1325–8

    Article  PubMed  CAS  Google Scholar 

  99. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999; 44: 219–32

    Article  PubMed  CAS  Google Scholar 

  100. Mata F. Effect of dextro-amphetamine on bitter taste threshold. J Neuropsychol 1963; 4: 315–20

    CAS  Google Scholar 

  101. Saini T, Edwards PC, Kimmes NS, et al. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prev Dent 2005; 3(3): 189–95

    PubMed  Google Scholar 

  102. Doty RL, Ferguson-Segall M. Odor detection performance of rats following d-amphetamine treatment: a signal detection analysis. Psychopharmacology 1987; 93(1): 87–93

    Article  PubMed  CAS  Google Scholar 

  103. Doty RL, Li C, Bagla R, et al. SKF 38393 enhances odor detection performance. Psychopharmacology 1998; 136(1): 75–82

    Article  PubMed  CAS  Google Scholar 

  104. Doty RL, Risser JM. Influence of the D-2 dopamine receptor agonist quinpirole on the odor detection performance of rats before and after spiperone administration. Psychopharmacology 1989; 98(3): 310–5

    Article  PubMed  CAS  Google Scholar 

  105. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26(7): 793–9

    PubMed  Google Scholar 

  106. Enghusen PH, Loft S, Andersen JR, et al. Disulfiram therapy — adverse drug reactions and interactions. Acta Psychiatr Scand Suppl. 1992; 369: 59–65

    Google Scholar 

  107. Fantino M, Hosotte J, Apfelbaum M. An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol 1986; 251(1): R91–6

    PubMed  CAS  Google Scholar 

  108. Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. Am J Physiol 1991 Jul; 261 (1 Pt 2): R59–63

    PubMed  CAS  Google Scholar 

  109. Komorowski JM, Komorowska A. Naloxone modulates gustatory perception, but not insulin and c-peptide release, in shamfed human-subjects. Int J Obes 1986; 10(2): 83–9

    PubMed  CAS  Google Scholar 

  110. Gaskell BA. Nonneoplastic changes in the olfactory epithelium: experimental studies. Environ Health Perspect 1990; 85: 275–89

    Article  PubMed  CAS  Google Scholar 

  111. Reed CJ. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev 1993; 25(1–2): 173–205

    Article  PubMed  CAS  Google Scholar 

  112. Frye RE, Schwartz BS, Doty RL. Dose-related effects of cigarette smoking on olfactory function. JAMA 1990; 263(9): 1233–6

    Article  PubMed  CAS  Google Scholar 

  113. Matulionis DH. Ultrastructure of olfactory epithelia in mice after smoke exposure. Ann Otolaryngol 1974; 83: 192–201

    CAS  Google Scholar 

  114. Patel SJ, Bollhoefer AD, Doty RL. Influences of ethanol ingestion on olfactory function in humans. Psychopharmacology 2004; 171(4): 429–34

    Article  PubMed  CAS  Google Scholar 

  115. Mair RG, McEntee WJ, Doty RL. Olfactory perception in Korsakoff s psychosis: correlation with brain noradrenergic activity. Neurology 1983; 33 Suppl. 2: 64–5

    Google Scholar 

  116. Vent J, Robinson AM, Gentry-Nielsen MJ, et al. Pathology of the olfactory epithelium: smoking and ethanol exposure. Laryngoscope 2004; 114(8): 1383–8

    Article  PubMed  CAS  Google Scholar 

  117. Murray C, Solish N. Metallic taste: an unusual reaction to botulinum toxin A. Dermatol Surg 2003; 29: 562–3

    Article  PubMed  Google Scholar 

  118. Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989; 119(2): 298–304

    PubMed  CAS  Google Scholar 

  119. Sarinopoulos I, Dixon GE, Short SJ, et al. Brain mechanisms of expectation associated with insula and amygdala response to aversive taste: implications for placebo. Brain Behav Immun 2006; 20(2): 120–32

    Article  PubMed  Google Scholar 

  120. Glendinning JI. Is the bitter rejection response always adaptive? Physiol Behav 1994; 56(6): 1217–27

    Article  PubMed  CAS  Google Scholar 

  121. Drewnowski A. The science and complexity of bitter taste. Nutr Rev 2001; 59(6): 163–9

    Article  PubMed  CAS  Google Scholar 

  122. Mattes RD. Influences on acceptance of bitter foods and beverages. Physiol Behav 1994; 56(6): 1229–36

    Article  PubMed  CAS  Google Scholar 

  123. Liem DG, De GC. Sweet and sour preferences in young children and adults: role of repeated exposure. Physiol Behav 2004; 83(3): 421–9

    Article  PubMed  CAS  Google Scholar 

  124. Liem DG, Bogers RP, Dagnelie PC, et al. Fruit consumption of boys (8–11 years) is related to preferences for sour taste. Appetite 2006; 46(1): 93–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported, in part, by Grants RO1 DC 004278 and RO1 AG 27496 from the National Institutes of Health, Bethesda, MD, USA. Dr Doty is a major shareholder in Sensonics, Inc., a manufacturer and distributor of tests of smell and taste function, and has served as a consultant to GlaxoSmithKline and Sepracor. Dr Bromley has participated on advisory panels and speaker bureaus for GlaxoSmithKline, Eli Lilly and Company, Pfizer, Cephalon and Forest Pharmaceuticals.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard L. Doty.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doty, R.L., Shah, M. & Bromley, S.M. Drug-Induced Taste Disorders. Drug-Safety 31, 199–215 (2008). https://doi.org/10.2165/00002018-200831030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831030-00002

Keywords

Navigation